Caribou Biosciences (NASDAQ: CRBU) Chief Medical Officer Tina M. Albertson executed a small open-market sale on February 24, 2026, disposing of 1,066 shares of common stock at $1.96 per share for proceeds of $2,089.
Since that trade, the share price has moved higher, trading as high as $2.14 and reflecting a 32% advance over the past week. Observers should note that InvestingPro highlights notable price volatility for the stock, a factor investors may weigh when interpreting insider activity.
Recent equity awards to the CMO
Four days prior to the sale, on February 20, 2026, Albertson received 55,000 shares of Caribou Biosciences common stock reported with a value of $0. These represent restricted stock units that will vest in four equal annual installments beginning on February 20, 2027.
On the same day she was also granted options to acquire 247,500 shares at an exercise price of $1.80 per share. Those options vest on a monthly basis, with full vesting scheduled by February 20, 2030.
Valuation and analyst note
InvestingPro analysis included in available reports indicates that the stock currently appears undervalued relative to its Fair Value assessment, for a company carrying a market capitalization of $203.76 million.
Separately, Clear Street initiated coverage with a Buy rating and a $13.00 price target, citing optimism about Caribou’s development of off-the-shelf allogeneic CAR-T cell therapies and the potential for those therapies to compete commercially in the market. That initiation represents a positive outlook from Clear Street’s analysts regarding the company’s development pathway.
What this reflects
The transactions recorded around February 20 and 24 show a mix of compensation-related awards and a small open-market sale by the CMO. The combination of RSUs, long-term option grants and a modest immediate sale is consistent with routine management equity activity; the broader market reaction included a sizable one-week price increase. Investors should balance insider transactions with analyst assessments and the noted price volatility when forming a view on the stock.